What is the role of Intraperitoneal (IP) therapy?
Robert Ozols, MD: The role of IP therapy will be debated extensively this summer at the GOG, but we do have some differing opinions about the importance of that. I think the only way to really answer that is ultimately in clinical trials. So, Maurie, would you like to comment on maintenance therapy? How you approach a woman who – with the data that is currently available? Maurie Markman, MD: I think it is complicated, but what we do know is that we can prolong the time to the development of recurrent disease based upon the SWOG/GOG trial; and, I think you have to tell the woman basically that. If she receives additional therapy, you can prolong the time to development of disease progression that may ultimately translate into survival, but we do not know for sure. And, the down side is she has to get more therapy, not have her hair grow back, and she will have to continue to come in and get treatment with some increased risks of neurotoxicity. But the counter-argument to that is that sh
